Radiopharmaceutical product supplier Pharmalucence has received U.S. Food and Drug Administration (FDA) clearance to expand the use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
To obtain FDA clearance for the expanded indication, the company said it conducted a systematic literature review and meta-analysis of published scientific articles that describe the efficacy and safety of SCI versus a blue dye used in lymph node localization.
